UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-37969 ENDRA LIFE SCIENCES INC. (Exact name of registrant as specified in its charter) Delaware 26-0579295 (State of incorporation) (I.R.S. Employer Identification ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended: December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission file number: 001-37969 ENDRA Life Sciences Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 2 ...

ENDRA Life Sciences Inc. (NASDAQ:NDRA) Q4 2022 Earnings Conference Call March 14, 2023 4:30 PM ET Company Participants Yvonne Briggs ??? LHA Investor Relations Francois Michelon ??? Chairman and Chief Executive Officer Michael Thornton ??? Chief Technology Officer Irina Pestrikova ??? Senior Director-Finance Conference Call Participants Vernon Bernardino ??? H.C. Wainwright & Company Edward Woo ??? Ascendiant Capital Operator Good afternoon, and welcome to the ENDRA Life Sciences Incorporated Fourth Quarter ...

Financial Data and Key Metrics Changes - For Q3 2022, operating expenses increased to $3.4 million from $2.7 million in Q3 2021, primarily due to higher spending on TAEUS commercialization and ongoing product development [34] - Research and development expenses rose by approximately $660,000 year-over-year, while sales and marketing expenses increased by about $140,000 as the company expanded its marketing efforts [35] - The net loss per share for Q3 2022 was $0.05, compared to a net loss of $0.06 per share in the same period last year [36] Business Line Data and Key Metrics Changes - The TAEUS system is focused on accurately measuring liver fat for early assessment of non-alcoholic fatty liver disease (NAFLD), which affects over 1 billion people globally [8] - Clinical study sites have obtained 95 study participant exams in 2022, nearly doubling the number from Q2 [16] Market Data and Key Metrics Changes - The market for NAFLD is growing at an annual rate of 12% to 15%, indicating a significant unmet clinical need for accessible, high-quality noninvasive diagnostics [26] - The company noted that MRI is too costly and liver biopsy is invasive, highlighting the need for better diagnostic tools [27] Company Strategy and Development Direction - The primary focus is on the effective collection of clinical data to enable a successful US regulatory submission and strong global commercialization [39] - The company is enhancing its intellectual property portfolio, with 56 patents issued globally, and is pursuing potential licensing opportunities for its technology [12] Management's Comments on Operating Environment and Future Outlook - Management expressed a growing optimism in the market, noting that clinicians are increasingly aware of the metabolic disease and the need for effective screening tools [44][47] - The company is well-positioned to meet the clinical needs despite macroeconomic factors such as supply chain issues and interest rates [46] Other Important Information - A special shareholder meeting was announced to approve a reverse stock split to maintain compliance with NASDAQ listing requirements, with no capital raise associated with it [14] - The company is offering flexible sales options, including rental and lease options for the TAEUS system, to facilitate market entry [33] Q&A Session Summary Question: Concerns about the macro environment at conferences - Management noted a growing optimism in the market, with a realization that current measurement tools may hinder development [44] Question: Speed of future scans with the TAEUS system - The company is targeting 200 scans to support commercialization efforts, with ongoing support for clinical investigators to collect necessary data effectively [52]

ENDRA Life Sciences Inc. (NASDAQ:NDRA) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Yvonne Briggs - IR Francois Michelon - Chairman and CEO Mike Thornton - Chief Technology Officer Renaud Maloberti - CCO Irina Pestrikova - Senior Director, Finance Conference Call Participants Edward Woo - Ascendiant Capital Vernon Bernardino - H.C. Wainwright Operator Good day everyone, and welcome to the ENDRA Life Sciences' Second Quarter 2022 Financial Results Conference Call. All part ...

FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-37969 ENDRA LIFE SCIENCES INC. (Exact name of registrant as specified in its charter) Delaware 26-0579295 (State of incorporation) (I.R.S. Employer Identification ...

ENDRA Life Sciences Inc. (NASDAQ:NDRA) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Yvonne Briggs - IR Francois Michelon - Chairman and CEO Mike Thornton - Chief Technology Officer Renaud Maloberti - CCO Irina Pestrikova - Senior Director, Finance Conference Call Participants Vernon Bernardino - H.C. Wainwright Edward Woo - Ascendiant Capital Operator Good afternoon everyone, and welcome to the ENDRA Life Sciences' First Quarter 2022 Financial Results Conference Call. All pa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER 001-37969 ENDRA LIFE SCIENCES INC. (Exact name of registrant as specified in its charter) Delaware 26-0579295 (State of incorporation) (I.R.S. Employer Identification ...

ENDRA Life Sciences, Inc. (NASDAQ:NDRA) Q4 2021 Earnings Conference Call March 30, 2022 4:30 PM ET Company Participants Yvonne Briggs - IR Francois Michelon - Chairman and CEO Renaud Maloberti - CCO Irina Pestrikova - Senior Director, Finance Conference Call Participants Ed Woo - Ascendiant Capital Operator Good day and welcome to the ENDRA Life Sciences' Fourth Quarter 2021 Financial Results Conference Call. All participants will be in a listen-only mode. [Operator Instructions] Please note this event is b ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended: December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission file number: 001-37969 ENDRA Life Sciences Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 2 ...